High prevalence of hyperhomocysteinemia related to folate deficiency and the 677C→T mutation of the gene encoding methylenetetrahydrofolate reductase in coastal West Africa

American Journal of Clinical Nutrition

Volumn 79, Issue 4, 2004, Pages 619-624

  Amouzou, Emile K ^a,b   Chabi, Nicodème W ^c   Adjalla, Charles E ^a   Rodriguez Guéant, Rosa M ^a   Feillet, François ^a   Villaume, Christian ^a   Sanni, Ambaliou ^c   Guéant, Jean Louis ^a,d  

^a INSERM   (France)

^b Laboratory of Biochemistry and Nutrition   (Togo)

^c Laboratory of Biochemistry and Molecular Biology   (Benin)

^d UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Cystatin C; Folate; Homocysteine; Methylenetetrahydrofolate reductase; Vitamin B 12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; CYSTATIN C; FOLIC ACID; HOMOCYSTEINE; CYSTATIN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2);

AFRICA; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; EVALUATION; FOLIC ACID DEFICIENCY; GENETIC POLYMORPHISM; GENOMICS; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; ADULT; BENIN; BLOOD; FEMALE; GENETICS; HEALTH SURVEY; MALE; METHODOLOGY; MIDDLE AGED; TOGO;

ADULT; BENIN; CYSTATINS; FEMALE; FOLIC ACID DEFICIENCY; GENOTYPE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POPULATION SURVEILLANCE; PREVALENCE; RISK FACTORS; TOGO; VITAMIN B 12;

EID: 2142819381     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/79.4.619     Document Type: Article

References (31)

1. Bollander-Gouaille C. Focus on homocysteine and the vitamins involved in its metabolism. 2nd ed. Paris: Spinger-Verlag, 2002.
2. Carmel R, Green R, Jacobsen WD, Rasmussen K, Florea M, Azen C. Serum cobalamin, homocysteine, and methylmalonic acid concentrations in a multiethnic elderly population: ethnic and sex differences in cobalamin and metabolite abnormalities. Am J Clin Nutr 1999;70:904-10.
3. Stabler SP, Allen HR, Fried PL, et al. Racial differences in prevalence of cobalamin and folate deficiencies in disabled elderly women. Am J Clin Nutr 1999;70:911-9.
4. Ubbink JB, Deport R, Vermaak WJ. Plasma homocysteine concentrations in a population with a low coronary heart disease prevalence. J Nutr 1996;126(suppl):1254S-7S.
5. Mudd SH, Levy HL, Skovky JR. Disorders of transsulfuration. In: Scriver CR, Beaudet AL, Sly WS, Valle DL, eds. The metabolic and molecular basis of inherited disease. Vol 2. 7th ed. New York: McGraw-Hill, 1995:1279-327.
6. Rosenblatt DS. Inherited disorder of folate transport and metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle DL, eds. The metabolic and molecular basis of inherited disease. Vol 2. 7th ed. New York: McGraw-Hill, 1995:3111-28.
7. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998;64:169-72.
8. Kluijtmans LA, van den Heuvel LPNJ, Boers G, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a risk factor for cardiovascular disease. Am J Hum Genet 1996;58:35-41.
9. Legnani C, Palareti G, Grauso, et al. Hyperhomocysteinemia and a common methylenetetrahydrofolate reductase mutation in patients with inherited thrombophilic coagulation defects. Arterioscler Thromb Vasc Biol 1997;17:2924-9.
10. Arruda VR, Von Zuben PM, Chiapirini LC, Annichino-Bizzacchi JM, Costa FF. The mutation ala-677-val in the methylenetetrahydrofolate reductase gene as a risk factor for arterial disease and venous thrombosis. Thromb Haemost 1997;77:818-21.
11. Van der Put NMJ, Grabeels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural tube-defects? Am J Hum Genet 1998;62:1044-51.
12. Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5:1867-71.
13. Stevenson RE, Schwartz CE, Du YZ, Adams MJ. Differences in methylene-tetrahydrofolate reductase genotype frequencies between whites and blacks. Am J Hum Genet 1997;60:229-30.
14. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:111-3.
15. Bosco P, Guéant-Rodriguez RM, Anello G, et al. Methionine synthase (MTR) 2756 (A→G) polymorphism, double heterozygosity methionine synthase 2756 AG/methionine synthase reductase (MTRR) 66 AG and elevated homocysteine concentration are three risk factors for having a child with Down syndrome. Am J Med Genet 2003;121A:219-24.
16. Gudnason V, Standbie D, Scoot J, Bowron A, Nicaud V, Humphries S. C677T (thermolabile alanine/valine) polymorphism in methylenetetrahydrofolate reductase (MTHFR): its frequency and impact on plasma homocysteine concentration in different European populations. Atherosclerosis 1998;136:347-54.
17. Botto LD, Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol 2000;151:862-77.
18. Rosenberg N, Murata M, Ikeda Y, et al. The frequent 5,10- methylenetetrahydrofolate reductase C677T polymorphism is associated with a common haplotype in whites, Japanese, and Africans. Am J Hum Genet 2002;70:758-62.
19. Enquêtes Budget Consommation (EBC). Phase urbaine, phase rurale. Lomé-Togo: Ministère du Plan, 1990 (in French).
20. Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
21. Guttmörsen AB, Ueland PM, Nesthus I, et al. Determinants and vitamins responsiveness of intermediate hyperhomocysteinemia (>40 mmol/l). The Hordaland Homocysteine study. J Clin Invest 1996;9:2174-83.
22. Franco RF, Araujo AG, Guerreiro JF, Elion J, Zago MA Analysis of the 677C→T mutation of the methylenetetrahydrofolate reductase gene in different ethnic groups. Thromb Haemost 1998;79:119-21.
23. Schneider JA, Rees DC, Liu YT, Clegg JB. Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. Am J Hum Genet 1998;62:1258-60.
24. Lopez MA, Zuniga J, Granados J, Mutchinick OM. Methylenetetrahydrofolate reductase C677T and A1298C gene mutations in an inbred group of Mazateco Indians: an ethnic genetic marker for some Amerindian populations. Am J Hum Genet 1999;65S:1156 (abstr).
25. Mutchinick OM, Lopez MA, Luna L, Waxman J, Babinsky VE. High prevalence of the thermolabile methylenetetrahydrofolate reductase variant in Mexico: a country with a very high prevalence of neural tube defects. Mol Genet Metab 1999;68:461-7.
26. Loktionov A, Vorster H, O'Neill IK, et al. Apolipoprotein E and methylenetetrahydrofolate reductase genetic polymorphisms in relation to other risk factors in UK Caucasians and black South Africans. Atherosclerosis 1999;145:125-35.
27. Rosenblatt DS, Whitehead VM. Cobalamin and folate deficiency: acquired and hereditary disorders in children. Semin Hematol 1999;36:19-34.
28. Pascal N, Amouzou EK, Sanni A, et al. Serum concentrations of sex hormone binding globulin are elevated in kwashiorkor and anorexia nervosa but not in marasmus. Am J Clin Nutr 2002;76:239-44.
29. Amvar A, Guéant JL, Abdelmouttaleb I, et al. Hyperhomocysteinemia is related to residual glomerular filtration and folate, but not to methylenetetrahydrofolate-reductase and methionine synthase polymorphisms, in supplemented end-stage renal disease patients undergoing hemodialysis. Clin Chem Lab Med 2001;39:747-52.
30. van der Put NMJ, van der Molen EF, Kluijtmans LAJ, et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinemia in neural tube defects and vascular disease. Q J Med 1997;90:511-7.
31. Wang XL, Cai H, Cranney G, Wilcken DE. The frequency of a common mutation of the methionine synthase gene in the Australian population and its relation to smoking and coronary artery disease. J Cardiovasc Risk 1998;5:289-95.